Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Nasdaq Inc (NDAQ) Price & Performance

Amylx Pharmaceuticals IncTrade
Nasdaq IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Nasdaq Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Nasdaq Inc trades at $95.63 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 20.1× Amylx Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXNDAQ
Market Cap
$2.64B$53.11B
Sector
HealthFinancials
52-Week High
$24.19$100.98
52-Week Low
$7.82$76.85
Enterprise Value
$2.39B$59.57B
Dividend Yield
1.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Nasdaq Inc

Nasdaq (NDAQ) trades at $95.26, down 0.38% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $8.26B in 2025, with net income reaching $1.79B and a profit margin of 21.64%. The company has beaten EPS estimates in recent quarters and announced the acquisition of LeveL Markets to expand its market infrastructure. Analyst consensus is strongly positive, with a $109.20 price target indicating ~15% upside.

Outlook remains favorable driven by earnings growth and strategic acquisitions, though risks include market volatility and integration challenges. The stock offers value through consistent profitability and dividend payments, supported by institutional confidence. Investors should weigh execution risks against the potential for continued expansion in financial services technology.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Nasdaq Inc

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

Read more on NDAQ